Evaluation of treat-and-extend-strategy-based ivom therapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00022939

Enrollment

650

Registered

2021-06-28

Start date

2020-06-05

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H35.3 H36.0

Interventions

Group 1: Retrospective evaluation of treat-and-extend IVOM therapy for macular edema caused by neovascular AMD or diabetes.

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: neovascular macular edema

Exclusion criteria

Exclusion criteria: Macular edema of non-neovascular origin, active retinal inflammation

Design outcomes

Primary

Measure	Time frame
Treatment outcome at defined time points [n], injection intervals [weeks], visual acuity [ETDRS letters at baseline and annually]	—

Secondary

Measure	Time frame
Proactive extension [weeks], Patients' adherence to their injection intervals [?weeks]. Therapy status at two years [end at dry retina, continuing therapy, discontinuation of therapy, loss of patient], Preparations [ranibizumab, aflibercept, bevacizumab], 1st, 2nd, and 3rd preparation changes [weeks], treatment duration [weeks], Number of intravitreal injections annually and in total [n]	—

Countries

Germany

Contacts

Public ContactIngo Volkmann

Medizinische Hochschule Hannover

volkmann.ingo@mh-hannover.de05115323061

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026